Zydus Lifesciences shares fall 1.04% as FYB206 keytruda biosimilar accepted for UDFDA review
Why did Zydus Lifesciences Ltd shares fall today?
Zydus Lifesciences Ltd shares fell by 1.04% today, with the stock trading at ₹1,127.2 as of Tuesday, 11:09 AM. The decline comes despite the company announcing a major milestone in its partnership with German biopharma firm Formycon, making it somewhat unusual for the stock to see selling pressure on a day of positive news flow.
On October 13, 2026, Zydus and Formycon jointly announced that FYB206, their proposed biosimilar to Merck's blockbuster cancer drug Keytruda, has been accepted for review by the US Food and Drug Administration (USFDA). This is a landmark moment, as FYB206 becomes the first publicly announced biosimilar to Keytruda to receive such acceptance from the USFDA. Notably, FYB206 was developed without requiring a comparative Phase III efficacy trial, following a development pathway that was agreed upon with the USFDA back in early 2025 — a significant time and cost advantage over traditional biosimilar development routes. Under the partnership, Zydus holds exclusive commercialization rights for the product in the United States and Canada, leveraging its established commercial infrastructure and experience in the North American market.
Despite this positive regulatory development, the stock's slight dip may be attributed to broader market movements, profit-booking by investors who had anticipated such an announcement, or general sector-wide weakness. It is also possible that the market had already priced in much of the positive news around FYB206's progress, leading to a "sell on news" reaction. Investors will likely be watching closely for further updates from the USFDA regarding the review timeline and eventual approval, which could serve as a major catalyst for the stock going forward.
What does Zydus Lifesciences Ltd do?
Zydus Lifesciences Ltd is a publicly traded pharmaceutical company listed on both the BSE Limited (Code: 532321) and the National Stock Exchange of India Limited (Code: Zyduslife). The company is engaged in the development of biosimilar products, among other pharmaceutical activities. It operates with a corporate secretary and compliance officer as part of its regulatory and governance structure, ensuring compliance with exchange listing requirements and investor communication obligations.
Zydus is actively involved in the development of biosimilar therapies, as evidenced by its collaboration with Formycon on FYB206, a proposed biosimilar to Keytruda®. This partnership has resulted in FYB206 becoming the first publicly announced biosimilar to Keytruda® to have its Biologics License Application accepted for review by the US Food and Drug Administration (USFDA). Notably, FYB206 was developed without a comparative Phase III efficacy study, reflecting the company's approach to biosimilar development. The filing and subsequent USFDA acceptance highlight Zydus Lifesciences' commitment to advancing biosimilar treatments and expanding its portfolio in the global pharmaceutical market.
Zydus Lifesciences Ltd Financials
In CroresZydus Lifesciences Ltd reported a revenue of ₹7,434.4 crores in the quarter ending March 2026, which increased to ₹7,802.0 crores in the quarter ending June 2026, reflecting a quarter-over-quarter revenue growth of approximately 4.95%. However, profit during the same period declined, with the company posting ₹1,272.5 crores in March 2026 compared to ₹939.8 crores in June 2026, representing a drop of approximately 26.15%. This indicates that while the company's top-line revenue expanded sequentially, its bottom-line profitability contracted during the April–June 2026 quarter, suggesting potential increases in operating costs, higher expenses, or other income-related factors that weighed on net profit despite stronger sales.
Zydus Lifesciences Ltd Shareholding Pattern
Promoter holding stands at 75.01% of the total share capital. Foreign Institutional Investors (FIIs) hold 7.05% stake in the company, while Domestic Institutional Investors (DIIs) hold 11.28%. Public shareholders hold the remaining 6.66% stake in Zydus Lifesciences Ltd.
Zydus Lifesciences Ltd FAQs
Q: Why did Zydus shares fall 1.04% today?
Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by UDFDA.. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Zydus Lifesciences Ltd?
As per the latest data, promoters hold 75.01% stake in Zydus Lifesciences Ltd, while FII holding stands at 7.05%. Domestic institutional investors hold 11.28%, and public shareholders account for 6.66% of the equity.
Q: What is the current stock price of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd shares are currently trading at ₹1127.2, recording a decline of 1.04% from the previous close.
Q: What is the market capitalization of Zydus Lifesciences Ltd?
The company currently has a market capitalization of ₹112438.63 crore, reflecting its valuation in the Indian equity market.